CD163+ macrophages restrain vascular calcification, promoting the development of high-risk plaque.
Atherosclerosis
Cell Biology
Macrophages
Plaque formation
Vascular Biology
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
08 03 2023
08 03 2023
Historique:
received:
28
09
2021
accepted:
20
01
2023
pubmed:
1
2
2023
medline:
10
3
2023
entrez:
31
1
2023
Statut:
epublish
Résumé
Vascular calcification (VC) is concomitant with atherosclerosis, yet it remains uncertain why rupture-prone high-risk plaques do not typically show extensive calcification. Intraplaque hemorrhage (IPH) deposits erythrocyte-derived cholesterol, enlarging the necrotic core and promoting high-risk plaque development. Pro-atherogenic CD163+ alternative macrophages engulf hemoglobin:haptoglobin (HH) complexes at IPH sites. However, their role in VC has never been examined to our knowledge. Here we show, in human arteries, the distribution of CD163+ macrophages correlated inversely with VC. In vitro experiments using vascular smooth muscle cells (VSMCs) cultured with HH-exposed human macrophage - M(Hb) - supernatant reduced calcification, while arteries from ApoE-/- CD163-/- mice showed greater VC. M(Hb) supernatant-exposed VSMCs showed activated NF-κB, while blocking NF-κB attenuated the anticalcific effect of M(Hb) on VSMCs. CD163+ macrophages altered VC through NF-κB-induced transcription of hyaluronan synthase (HAS), an enzyme that catalyzes the formation of the extracellular matrix glycosaminoglycan, hyaluronan, within VSMCs. M(Hb) supernatants enhanced HAS production in VSMCs, while knocking down HAS attenuated its anticalcific effect. NF-κB blockade in ApoE-/- mice reduced hyaluronan and increased VC. In human arteries, hyaluronan and HAS were increased in areas of CD163+ macrophage presence. Our findings highlight an important mechanism by which CD163+ macrophages inhibit VC through NF-κB-induced HAS augmentation and thus promote the high-risk plaque development.
Identifiants
pubmed: 36719758
pii: 154922
doi: 10.1172/jci.insight.154922
pmc: PMC10077470
doi:
pii:
Substances chimiques
CD163 antigen
0
NF-kappa B
0
Hyaluronic Acid
9004-61-9
Apolipoproteins E
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL141425
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Atherosclerosis. 2017 Dec;267:78-89
pubmed: 29101839
Free Radic Biol Med. 2013 Aug;61:464-72
pubmed: 23624304
JACC Cardiovasc Imaging. 2009 Oct;2(10):1175-83
pubmed: 19833306
Antioxid Redox Signal. 2013 Jun 10;18(17):2254-63
pubmed: 22793784
Atherosclerosis. 2015 Aug;241(2):772-82
pubmed: 26058741
Nat Rev Cardiol. 2016 Feb;13(2):79-98
pubmed: 26503410
Circ Res. 2017 Jun 23;121(1):19-30
pubmed: 28438779
Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):724-36
pubmed: 24558104
Genes Dev. 1998 May 1;12(9):1260-8
pubmed: 9573043
Eur Heart J Cardiovasc Imaging. 2018 Aug 1;19(8):850-858
pubmed: 29617981
Curr Pharm Des. 2012;18(11):1519-30
pubmed: 22364136
Nat Genet. 2021 Mar;53(3):403-411
pubmed: 33633365
Nat Med. 2019 Aug;25(8):1280-1289
pubmed: 31359001
Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2391-6
pubmed: 15472131
Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):489-94
pubmed: 12615658
Cell Mol Life Sci. 2020 May;77(10):1919-1932
pubmed: 31720740
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):714-732
pubmed: 31996022
Circulation. 2010 Nov 30;122(22):2313-22
pubmed: 21098434
Nucleic Acids Res. 2019 Jul 2;47(W1):W212-W224
pubmed: 31114921
TH Open. 2021 Apr 14;5(2):e113-e124
pubmed: 33870075
N Engl J Med. 2003 Dec 11;349(24):2316-25
pubmed: 14668457
Nature. 1997 Mar 6;386(6620):78-81
pubmed: 9052783
J Am Coll Cardiol. 2012 Jan 10;59(2):166-77
pubmed: 22154776
J Biol Chem. 2007 Apr 13;282(15):11530-9
pubmed: 17307735
Nat Genet. 2022 Jun;54(6):804-816
pubmed: 35590109
Circulation. 1999 Nov 23;100(21):2168-76
pubmed: 10571976
Herz. 2001 Jun;26(4):239-44
pubmed: 11479935
Circulation. 2019 Apr 23;139(17):2032-2048
pubmed: 30717607
Circulation. 2005 May 31;111(21):2768-75
pubmed: 15911695
Thromb Res. 2011 Aug;128(2):117-23
pubmed: 21636112
Atherosclerosis. 1999 Dec;147(2):253-61
pubmed: 10559511
Eur Heart J. 2014 Jul 1;35(25):1683-93
pubmed: 24126875
Biochim Biophys Acta. 1999 Jan 11;1448(3):416-24
pubmed: 9990294
Nat Rev Cardiol. 2015 Jan;12(1):10-7
pubmed: 25367649
J Am Coll Cardiol. 2015 Apr 7;65(13):1273-1282
pubmed: 25835438
Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):2587-92
pubmed: 11116057
Lab Invest. 2018 Oct;98(10):1320-1332
pubmed: 29785051
J Am Heart Assoc. 2018 Jan 4;7(1):
pubmed: 29301759
Kidney Int. 2012 Jul;82(1):34-44
pubmed: 22437419
JACC Cardiovasc Imaging. 2018 Jan;11(1):127-142
pubmed: 29301708
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Adv Drug Deliv Rev. 2016 Feb 1;97:186-203
pubmed: 26541745
Cardiovasc Res. 2016 Nov 01;112(2):606-616
pubmed: 27671804
J Biol Chem. 2010 Aug 6;285(32):24639-45
pubmed: 20522558
Front Pharmacol. 2020 May 08;11:661
pubmed: 32457633
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):638-655
pubmed: 31893948
Atherosclerosis. 2020 Aug;306:85-95
pubmed: 32654790
Nat Commun. 2015 Aug 05;6:7792
pubmed: 26242746
Atherosclerosis. 2013 Jul;229(1):124-9
pubmed: 23578355
J Clin Invest. 2018 Mar 1;128(3):1106-1124
pubmed: 29457790
Intern Med. 2019 Jul 1;58(13):1907-1912
pubmed: 30918181
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Nature. 2001 Jan 11;409(6817):198-201
pubmed: 11196644
Circulation. 1995 Oct 15;92(8):2157-62
pubmed: 7554196